Jacob Lalezari - Articles and news items

Boehringer Ingelheim logo

Investigational interferon-free regimen demonstrates undetectable hepatitis C virus in all patients reaching end of treatment in ongoing Phase II trial

Industry news / 8 October 2013 / Boehringer Ingelheim

“These results are promising particularly because they show the potential to evaluate harder-to-treat populations…”

Boehringer Ingelheim logo

Boehringer Ingelheim broadens efforts for interferon-free hepatitis C treatments through clinical collaboration with Presidio Pharmaceuticals

Industry news, News / 10 September 2013 / Boehringer Ingelheim

Boehringer Ingelheim announced the completion of patient enrolment for a Phase IIa clinical trial…

 

The deadline for submissions to the EPR Awards is 9 June 2017! Entry is FREE, so don't delay...
+